Bohai Pharmaceuticals Group, Inc.  

(Public, OTCMKTS:BOPH)   Watch this stock  
Find more results for PINK:BOPH
-0.001 (-0.12%)
Dec 22 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.85 - 0.88
52 week 0.30 - 2.06
Open 0.85
Vol / Avg. 803.00/7,953.00
Mkt cap 16.57M
P/E 0.77
Div/yield     -
EPS 1.10
Shares 19.52M
Beta 1.81
Inst. own     -

Key stats and ratios

Q3 (Sep '14) 2014
Net profit margin 17.07% 12.50%
Operating margin 23.77% 18.51%
EBITD margin - 21.67%
Return on average assets 19.30% 12.49%
Return on average equity 27.64% 18.40%
Employees 660 -
CDP Score - -


No.7 Tianzheng Road, Laishan District
YANTAI, SDG 264003
+86-888-9237679 (Phone)

Website links


Bohai Pharmaceuticals Group, Inc. (BOPH) is engaged in the production, manufacturing and distribution of herbal pharmaceuticals based on traditional Chinese medicine (TCM), in the People�s Republic of China. The Company�s operations are exclusively in China. The Company's medicines address rheumatoid arthritis, viral infections, gynecological diseases, cardio vascular issues and respiratory diseases. The Company obtained Drug Approval Numbers for 29 varieties of traditional Chinese herbal medicines. The Company produces 19 varieties of approved traditional Chinese herbal medicines in seven delivery systems: tablets, granules, capsules, formulations, concentrated powder, tincture and medicinal wine. Of these 19 products, 12 are prescription drugs and seven are over the counter (OTC) products. In August 2011, the Company obtained DANs for another five varieties. On August 8, 2011, the Company acquired Yantai Tianzheng Pharmaceutical Co., Ltd.

Officers and directors

Hongwei Qu Chairman of the Board, President, Chief Executive Officer
Age: 37
Chunhong Jiang Treasurer, Secretary
Age: 48
THOMAS Z TAN Independent Director
Age: 51
Chengde Wang Independent Director
Age: 65